Retinoides para a prevenção e tratamento das queratoses actínicas

Ianhez, Mayra; Fleury Junior, Luiz Fernando Fróes; Miot, Hélio Amante; Bagatin, Edileia

doi:10.1590/abd1806-4841.20131803

Acessibilidade / Reportar erro

Brasil

Anais Brasileiros de Dermatologia

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Review • An. bras. dermatol. 88 (4) • Ago 2013 • https://doi.org/10.1590/abd1806-4841.20131803 copiar

Retinoides para a prevenção e tratamento das queratoses actínicas

Autoria SCIMAGO INSTITUTIONS RANKINGS

A queratose actínica é uma causa comum de consultas dermatológicas e apresenta forte associação com o carcinoma espinocelular. Muitas substâncias são utilizadas para seu tratamento e prevenção, assim como os retinoides. Entretanto, muitos estudos sobre retinoides salientam seu uso no tratamento e prevenção de cânceres de pele não melanoma. Neste artigo, nós revisamos estudos que avaliam o uso dos retinoides sistêmicos e tópicos para pacientes imunocompetentes e imunossuprimidos com queratoses actínicas, como desfechos primários e secundários. A maioria destes estudos mostra redução na contagem das queratoses actínicas após o tratamento com retinóides. Além disso, ajustes no delineamento dos estudos deveriam ser feitos quanto à falta de padronização da dose, ausência de grupos controle, número pequeno de pacientes e tempo curto de seguimento. Ensaios clínicos cegos, randomizados e controlados com tamanho amostral adequado tendo como alvo específico as queratoses actínicas são necessários para esclarecer o real benefício dos retinoides tópicos e/ou orais. A comparação da eficácia e segurança entre os retinoides orais e tópicos na prevenção e tratamento dos cânceres de pele não melanoma e queratoses actínicas é um pré-requisito essencial para o estabelecimento de novas estratégias para o controle destas condições.

Ceratose actínica; Isotretinoína; Quimioprevenção; Retinóides; Tretinoína

Retinoids	Examples	Administration route
First generation (non-aromatic)	Tretinoin	Topical
	Isotretinoin	Topical and systemic
	Alitretinoin	Systemic

Second generation (mono-aromatic)	Etretinate	Acitretin
	Systemic	Systemic

Third generation (poly-aromatic)	Adapalene	Topical
	Tazarotene	Topical
	Bexarotene	Systemic

Skin lesions	Author (year)	Retinoids
AK/SCC	Kelly (1991)²⁶	Etretinate; acitretin; acitretin
	Bavinck (1994)²⁷
	De Sevaux (2003)²⁸
AK / BCC	Bollag (1970)²⁹; Hughes (1998)³⁰	Tretinoin etretinate
AK / warts	Euvrard (1992)³¹	Tretinoin
AK / warts/SCC	Rook (1995)²⁵	Tretinoin x etretinate + tretinoin
AK / BCC/SCC	Majewski (1994),³² Yuan (1995)³³ Euvrard (1998),³⁴ George (2002),³⁵McNamara(2002)³⁶	Isotretinoin + calcitriol acitretin; adapalene; acitretin; acitretin
AK / warts/BCC/SCC	Shuttleworth (1988),³⁷ McKenna (1999)³⁸	Etretinate; acitretin
AK alone	Moriarty (1982),¹⁸ Kligman (1991),³⁹ Misiewicz (1991),⁴⁰ Alizerai (1994),⁴¹ Moglia (1997),⁴² Campanelli (2002),⁴³ Smit (2002),⁴⁴ Smit (2004)⁴⁵	Etretinate; tretinoin 0.05%; Ro-14-9706 x tretinoin 0.05%; isotretinoin 0.1%; retinoid fenretinide; retinaldehyde 0.05%; tretinoin 0.02% x calcipotriol; acitretin

Author (year)	Study design Nº patients	Drug and treatment duration	Results
Moriarty (1982)18	Cross-over, open, randomized, controlled; 50 immunocompetent patients	Etretinate 5mg 3x/day versus placebo, 2months, after, the groups were swapped for 2 more months (placebo x etretinate)	84% of the etretinate group had complete or partial response compared to 5% in the placebo group
Shuttleworth (1988) 37	Cases series 6 transplanted patients	Etretinate 1mg/kg/day, 6months	"Almost" complete resolution of neoplastic and pre-neo-plastic lesions in 4 patients, partial response in 1 patient
Kelly (1991)26	Cases series 4 transplanted patients	Etretinate 50mg/day, 8-13months	AKs were not counted but they became less severe after treatment
Bavinck (1995)27	Double-blind, randomized, controlled 44 transplanted patients	Acitretin 30mg/ day versus placebo, 6 months	13.4% of patients in the acitretin group saw decreases in the number of AKs, while in the placebo group, 28.2% of the patients saw increases
Majewski (1994)32	Cases series 4 immunocompetent patients	Isotretinoin 0.4-0.5mg/kg/day + calci-triol 0.5-1µg, 12months, approximately	Patient 1- complete clearance; Patients 2 and 3- AK regression about 50 to 80%; Patient 4 - regression of 40% of AKs in number and size
Yuan (1995)33	Cases series 15 transplanted patients	Acitretin 10-50mg/day, 6-12 months	The number of skin cancers decreased in 4 of the 6 patients. All warts and AKs had improvement in all patients (without counting)
Rook (1995)25	Open, non-randomized, controlled 11 transplanted patients	Group 1= 7 patients (tretinoin 0.025% to 0.05% according to tolerance) + (etretinate 10mg/day or alternate days), 6 months according to improvement in AKs Group 2= 4 patients (tretinoin 0.025 to 0.05%, according to tolerance)	Both groups obtained a decrease in the number of AKs and an improvement in the number of Langerhans cells. Four patients in the combined group obtained almost 50% regression of AKs while 2 in the tretinoin group obtained improvement, after six months
Hughes (1998)30	Cases series 15 immunocompetent patients	Etretinate,18 month follow-up 1st month - 1.5mg/kg/day 2nd and 3rd months - 0.75mg/kg/day	Only 12 patients with AKs completed the study, with an average reduction in the number of AKs before and after treatment of 12.73 to 5.82
McKenna (1999)38	Cases series, 16 transplanted patients	Acitretin 0.3mg/kg/day, 5 years	There was significant improvement in warts and AKs, but they were not counted
George (2002)35	Cross-over, open, randomized controlled 23 immunocompetent patients	Group 1: Acitretin 25mg/day (variable) + placebo, 12months Group 2: Placebo + Acitretin 25mg/day (variable), 12months	In the acitretin group, complete clearance or reduction in number of AKs occurred in all patients, except one. In the placebo group, there was an increase of 50% in the number of AKs in 3 patients and 6 remained with no significant change
McNamara (2002)36	Cases series 5 transplanted patients	Acitretin 10 or 25mg/day, 10-24 months	AKs seemed to be in varying degrees of resolution with treatment but they were not counted
De Sevaux (2003)28	Open, randomized controlled 26 transplanted patients	Acitretin Group 1: 0.4mg/kg/ day, 12 months Group 2: 0.4mg/kg/ day, 3 months + 0.2mg/kg/ day, 9 months	Significant reduction in number of AKs in both groups after 2 months, but no difference between the groups at any particular point
Smit (2004)45	Cases series 33 transplanted patients	Acitretin: up to 0.4mg/kg/ day, 3months (biopsy of AKs)	Reduction of 44% in epidermal thickness due to stratum corneum, no difference in expression of p53 and Ki67 and an increase in the expression of K13 and K19 after treatment with acitretin

Author (year)	Study design Nº patients	Drug and treatment duration	Results
Bollag (1970)29	Case series 60 immunocompetent patients	Tretinoin 0.1% and 0.3% cream, 2x/day, in AKs and lx/day, occlusive in BCCs, 3 to 8 weeks	44 patients showed total or more than 50% of regression of the AKs. Tretinoin 0,3% showed higher rates of regression, as well as the face, compared to the upper limbs
Purcell (1986)46	Double-blind, non-randomized, controlled; 24 immuno-competent patients (8 drop out)	Tretinoin 0.05% ointment x placebo, 12months	There was no statistically significant difference between the groups in relation to the number of AKs
Kligman (1991)39	Double-blind, controlled 1265 immunocompetent patients (multicentered)	Tretinoin 0.05% x tretinoin 0.1% x placebo ointment, up to 15 months	The most effective treatment for reducing AKs was 0.1% tretinoin, applied twice daily (P.001). An excellent response was observed in 73% of tretinoin-treated patients compared with only 40% of placebo
Misiewicz (1991)40	Double-blind, randomized, controlled, 25 immunocom-petent patients	Ro 14-9706 x tretinoin 0.05% ointment, 16 weeks	Decrease of 37.8% in AK numbers with Ro 14-9706, while with tretinoin, the decrease was 30.3%. There was no difference between the two drugs, although Ro 14-9706 was better tolerated
Euvrard (1992)31	Double-blind, randomized, controlled, 22 transplanted patients	Tretinoin 0.05% ointment x placebo, 3 months	Reduction of 45% versus 23% of AKs in the tretinoin 0.05% group versus placebo, respectively
Alizerai (1994)41	Double-blind, randomized, placebo-controlled 100 immunocompetent patients	Isotretinoin 0.1% ointment, 2x/day x placebo, 24 weeks	66% of the patients with isotretinoin versus 45% of the patients with placebo had a partial or complete response, whereas 34% of patients with isotretinoin versus 55% of patients with placebo had no response or worsening on the face
Rook (1995)25	Open, non-randomized, controlled 11 transplanted patients	Group 1= 7 patients (tretinoin 0.025% to 0.05% according to tolerance) + (etretinate 10mg/day or alternate days), 6 months according to AK improvement, Group 2= 4 patients (tretinoin 0.025 to 0.05%, according to tolerance)	Both groups obtained a decrease in the number of AKs and an improvement in the number of Langerhans cells. Four patients in the combined group obtained almost 50% of regression of AKs, while 2 in the tretinoin group obtained improvement, after six months
Moglia (1997)42	Case series 18 immunocompetent patients	Retinoid fenretinide 2x/day, 3months	Complete and partial regression was observed in 56% and 44% of patients, respectively
Euvrard (1998)34	Randomized, controlled 40 transplanted patients	Adapalene 0.1% x adapalene 0.3%, 6 months	Reduction of 32% versus 21% in AKs number with concentrations of 0.3% and 0.1% respectively
Campanelli (2002)43	Case series 61 immunocompetent patients	Retinaldehyde 0.05%, 6-142 months	37% of the patients aged over 60 and 10% between 41-60 years developed AKs during the treatment. Retinaldehyde alone does not appear to have prophylactic effects on the development of AKs
Smit (2002)44	Open, non-randomized, controlled, 13 immunocom-petent patients	Group 1: Tretinoin 0,02%	There were no significant differences in clinical, histological and immunohistochemical parameters between the four different therapies during a 6-week treatment period.
		Group 2: calcipotriol
		Group 3: both
		Group 4: emollient
		All 2x/day, 6 weeks

Sociedade Brasileira de Dermatologia Av. Rio Branco, 39 18. and., 20090-003 Rio de Janeiro RJ, Tel./Fax: +55 21 2253-6747 - Rio de Janeiro - RJ - Brazil
E-mail: revista@sbd.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] MAILING ADDRESS: Mayra Ianhez, Universidade Federal de Goiás, Ambulatório de Dermatologia/ Hospital das Clínicas, Primeira Avenida s/n, Setor Leste Universitário, 74605-020 - Goiânia - GO, Brazil, E-mail: ianhez@hotmail.com